Clinical Trial Update: the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia [EARLY_Phase 1]

View source ↗

Summary

An ongoing early-phase trial evaluating the safety and efficacy of HGI-002 Injection in transfusion-dependent α-thalassemia, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia

Drugs mentioned

• HGI-002 Injection (HGI-002)

Snippet

Sponsor: Shenzhen Hemogen | Conditions: α-thalassemia | EARLY_Phase 1 | Status: RECRUITING